AbbVie (ABBV) Cost of Revenue (2012 - 2026)

AbbVie (ABBV) has reported Cost of Revenue for 15 consecutive years, with $4.3 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cost of Revenue fell 1.27% year-over-year to $4.3 billion in Q2 2026; TTM through Jun 2026 was $18.4 billion, a 8.31% increase from a year earlier, with the FY2025 full-year figure at $18.2 billion, up 7.69% from the prior year.
• Cost of Revenue was $4.3 billion for Q2 2026 at AbbVie, up from $4.2 billion in the prior quarter.
• Over five years, Cost of Revenue peaked at $6.5 billion in Q3 2023 and troughed at $4.0 billion in Q1 2023.
• A 5-year average of $4.5 billion and a median of $4.2 billion in 2023 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue jumped 36.79% in 2023 and slumped 35.05% in 2024, its largest moves.
• Over 5 years, Cost of Revenue stood at $4.2 billion in 2022, then jumped by 36.79% to $5.7 billion in 2023, then declined by 22.93% to $4.4 billion in 2024, then climbed by 3.55% to $4.6 billion in 2025, then slipped by 5.73% to $4.3 billion in 2026.
• The last three Cost of Revenue figures came in at $4.3 billion (Q2 2026), $4.2 billion (Q1 2026), and $4.6 billion (Q4 2025), per Business Quant data.